Biogen Reports Strong FY25 EPS Beat, Growth Product Momentum, and Key Pipeline Progress Amidst Q4 Declines and FY26 Revenue Outlook

summarizeSummary

Biogen reported mixed Q4 2025 results with revenue and EPS declines, but exceeded its full-year 2025 Non-GAAP EPS guidance and highlighted strong growth in key products and significant pipeline advancements. The company provided 2026 guidance expecting a mid-single digit revenue decline but stable Non-GAAP EPS.

check_boxKey Events

• Exceeded Full-Year 2025 Non-GAAP EPS Guidance

  Biogen reported full-year 2025 Non-GAAP diluted EPS of $15.28, surpassing the upper end of its guidance range of $14.50 to $15.00.

• Mixed Q4 2025 Financial Performance

  Fourth quarter 2025 total revenue was $2.3 billion (down 7% year-over-year) and Non-GAAP diluted EPS was $1.99 (down 42% year-over-year).

• Strong Growth in Key Products

  LEQEMBI global in-market sales grew 54% year-over-year to $134 million in Q4 2025. SKYCLARYS and ZURZUVAE also showed strong demand growth, with overall growth products up 6% year-over-year in Q4 and 19% for the full year.

• Provided Full-Year 2026 Financial Guidance

  The company expects full-year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25, with total revenue projected to decline by a mid-single digit percentage.

auto_awesomeAnalysis

Biogen's latest earnings report presents a mixed but overall positive picture for investors. While the fourth quarter saw declines in total revenue and GAAP/Non-GAAP EPS, the company significantly exceeded its full-year 2025 Non-GAAP diluted EPS guidance, demonstrating strong financial execution. Key growth products like LEQEMBI, SKYCLARYS, and ZURZUVAE showed robust demand, which is critical for future revenue streams as older MS products decline. The pipeline advancements, including FDA Priority Review for LEQEMBI's subcutaneous treatment and Breakthrough Therapy Designation for litifilimab, signal potential future value. However, the forecast for a mid-single digit revenue decline in 2026, primarily due to continued erosion in the MS franchise, remains a headwind. Investors will be watching if the growth products and pipeline can sufficiently offset these declines to maintain stable EPS and drive long-term value, especially with the stock currently trading near its 52-week high.